☰

Sabrina Armstrong - Publications

Affiliations: 
Institute of Medical Science University of Toronto, Toronto, ON, Canada 
Tree Info Grants Similar researchers Related pubs Distance to... Nearest Nobel PubMed Report error

33 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2022 Menon S, Armstrong S, Hamzeh A, Visanji NP, Sardi SP, Tandon A. Alpha-Synuclein Targeting Therapeutics for Parkinson's Disease and Related Synucleinopathies. Frontiers in Neurology. 13: 852003. PMID 35614915 DOI: 10.3389/fneur.2022.852003  0.382
2021 Heikamp EB, Henrich JA, Perner F, Wong EM, Hatton C, Wen Y, Barwe SP, Gopalakrishnapillai A, Xu H, Uckelmann HJ, Takao S, Kazansky Y, Pikman Y, McGeehan GM, Kolb EA, ... ... Armstrong SA, et al. The Menin-MLL1 interaction is a molecular dependency in NUP98-rearranged AML. Blood. PMID 34582559 DOI: 10.1182/blood.2021012806  0.321
2021 Perner F, Schnoeder TM, Xiong Y, Jayavelu AK, Mashamba N, Santamaria NT, Huber N, Todorova K, Hatton C, Perner B, Eifert T, Murphy C, Hartmann M, Hoell JI, Schröder N, ... ... Armstrong SA, et al. YBX1 mediates translation of oncogenic transcripts to control cell competition in AML. Leukemia. PMID 34465866 DOI: 10.1038/s41375-021-01393-0  0.322
2020 Uckelmann HJ, Armstrong SA. Chromatin Complexes Maintain Self-Renewal of Myeloid Progenitors in AML: Opportunities for Therapeutic Intervention. Stem Cell Reports. PMID 32559456 DOI: 10.1016/J.Stemcr.2020.05.013  0.33
2019 Dzama MM, Taubert MC, Kunz K, Rausch J, Chen CD, Mupo A, Hähnel P, Theobald M, Kindler T, Koche RP, Vassiliou GS, Armstrong SA, Kühn MW. Combined Targeting of the Menin-MLL1 Chromatin Complex and FLT3 As a Novel Therapeutic Concept Against NPM1 Mutant or MLL-Rearranged AML with Mutated FLT3 Blood. 134: 1441-1441. DOI: 10.1182/blood-2019-122847  0.311
2018 Sun Y, Zhou B, Mao F, Xu J, Miao H, Zou Z, Phuc Khoa LT, Jang Y, Cai S, Witkin M, Koche R, Ge K, Dressler GR, Levine RL, Armstrong SA, et al. HOXA9 Reprograms the Enhancer Landscape to Promote Leukemogenesis. Cancer Cell. PMID 30270123 DOI: 10.1016/J.Ccell.2018.08.018  0.301
2018 Park S, Cho H, Thornton A, Barlowe TS, Chou T, Chhangawala S, Fairchild L, Chow A, Taggart J, Schurer A, Gruet A, Witkin M, Kim JH, Shevach E, Krivstov A, ... Armstrong SA, et al. IKZF2 Drives Self-Renewal and Blocks Myeloid Differentiation Programs in Myeloid Leukemic Stem Cells Blood. 132: 3881-3881. DOI: 10.1182/Blood-2018-99-115034  0.31
2017 Valerio DG, Xu H, Chen CW, Hoshii T, Eisold ME, Delaney C, Cusan M, Deshpande AJ, Huang CH, Lujambio A, Zheng YG, Zuber J, Pandita TK, Lowe SW, Armstrong SA. Histone acetyltransferase activity of MOF is required for MLL-AF9 leukemogenesis. Cancer Research. PMID 28202522 DOI: 10.1158/0008-5472.Can-16-2374  0.303
2017 Vu L, Prieto C, Amin EM, Minuesa G, Chhangawala S, Vidal MC, Krivtsov A, Chou T, Chow A, Barlowe T, Taggart J, Tivnan P, Deering RP, Chu LP, Gonen M, ... ... Armstrong S, et al. Abstract IA13: RNA regulators and the control of self-renewal Clinical Cancer Research. 23. DOI: 10.1158/1557-3265.Hemmal17-Ia13  0.316
2016 Kühn MW, Song E, Feng Z, Sinha A, Chen CW, Deshpande AJ, Cusan M, Farnoud N, Mupo A, Grove C, Koche R, Bradner JE, de Stanchina E, Vassiliou GS, Hoshii T, ... Armstrong SA, et al. Targeting Chromatin Regulators Inhibits Leukemogenic Gene Expression in NPM1 Mutant Leukemia. Cancer Discovery. PMID 27535106 DOI: 10.1158/2159-8290.Cd-16-0237  0.308
2016 Chen CD, Delaney C, Xu H, Koche R, Lujambio Goizueta A, Hoshii T, Cusan M, Chabon J, Valerio DG, Kuehn M, Wang X, Cai S, Chu SH, Chen YK, He J, ... ... Armstrong SA, et al. An Epigenetic Regulator Screen Identifies Novel Targets That Sensitize MLL-Rearranged Leukemia to DOT1L Inhibition Blood. 128: 571-571. DOI: 10.1182/Blood.V128.22.571.571  0.302
2016 Ramaswamy K, Forbes L, Brown FC, Koche R, Gindin T, Minuesa G, Kharas MG, Krivtsov A, Armstrong SA, Still E, de Stanchina E, Isenhart R, Guo G, Knoechel B, Kentsis A. Peptidomimetic Blockade of MYB in Acute Myeloid Leukemia Blood. 128: 3945-3945. DOI: 10.1182/BLOOD.V128.22.3945.3945  0.32
2016 Valerio DG, Xu H, Chen C, Hoshii T, Eisold M, Delaney C, Cusan M, Deshpande AJ, Huang C, Lujambio A, Zheng G, Pandita TK, Lowe SW, Armstrong SA. Abstract 2694: Histone acetyltransferase activity of MOF is required for MLL-AF9 leukemogenesis Cancer Research. 76: 2694-2694. DOI: 10.1158/1538-7445.Am2016-2694  0.308
2015 Chen CW, Armstrong SA. Targeting DOT1L and HOX Gene Expression in MLL-Rearranged Leukemia and Beyond. Experimental Hematology. PMID 26118503 DOI: 10.1016/J.Exphem.2015.05.012  0.308
2015 Smitheman K, Cusan M, Liu Y, Butticello M, Pappalardi M, Foley J, Federowicz K, Aller GV, Kasparec J, Tian X, Suarez D, Schneck J, Carson J, McDevitt P, Ho T, ... ... Armstrong S, et al. Abstract 3513: Inhibition of LSD1 for the treatment of cancer Cancer Research. 75: 3513-3513. DOI: 10.1158/1538-7445.Am2015-3513  0.302
2014 Bruedigam C, Bagger FO, Heidel FH, Paine Kuhn C, Guignes S, Song A, Austin R, Vu T, Lee E, Riyat S, Moore AS, Lock RB, Bullinger L, Hill GR, Armstrong SA, et al. Telomerase inhibition effectively targets mouse and human AML stem cells and delays relapse following chemotherapy. Cell Stem Cell. 15: 775-90. PMID 25479751 DOI: 10.1016/J.Stem.2014.11.010  0.303
2014 Placke T, Faber K, Nonami A, Putwain SL, Salih HR, Heidel FH, Krämer A, Root DE, Barbie DA, Krivtsov AV, Armstrong SA, Hahn WC, Huntly BJ, Sykes SM, Milsom MD, et al. Requirement for CDK6 in MLL-rearranged acute myeloid leukemia. Blood. 124: 13-23. PMID 24764564 DOI: 10.1182/Blood-2014-02-558114  0.333
2014 Riedel S, Bernt KM, Haladyna J, Bezzant M, Stevens B, Pollyea DA, Sinha AU, Armstrong SA, Wei Q, Jordan CT, Neff T. Targeting Meningeoma-1 Driven AML through Epigenetic Modulation of the Cell of Origin Blood. 124: 838-838. DOI: 10.1182/Blood.V124.21.838.838  0.314
2014 Danis E, Yamauchi T, Echanique K, Haladyna J, Xie H, Zhu N, Riedel S, Bernt KM, Orkin SH, Armstrong SA, Neff T. Context Dependent Role of Polycomb Repressive Complex 2 in Acute Leukemia Blood. 124: 610-610. DOI: 10.1182/Blood.V124.21.610.610  0.327
2013 Krivtsov AV, Figueroa ME, Sinha AU, Stubbs MC, Feng Z, Valk PJM, Delwel R, Döhner K, Bullinger L, Kung AL, Melnick AM, Armstrong SA. Cell of origin determines clinically relevant subtypes of MLL-rearranged AML Leukemia. 27: 852-860. PMID 23235717 DOI: 10.1038/Leu.2012.363  0.311
2013 David Chen C, Sinha AU, Qi J, Deshpande AJ, Zhu N, Koche R, Eng R, Chang J, Hahn WC, Bradner JE, Armstrong SA. Genome-Wide RNAi Screen Identifies The Mechanistic Role For DOT1L In MLL-Rearranged Leukemia Blood. 122: 598-598. DOI: 10.1182/Blood.V122.21.598.598  0.323
2013 Kruger RG, Mohammad H, Smitheman K, Cusan M, Liu Y, Pappalardi M, Federowicz K, Van Aller G, Kasparec J, Tian X, Suarez D, Rouse M, Schneck J, Carson J, McDevitt P, ... ... Armstrong SA, et al. Inhibition Of LSD1 As a Therapeutic Strategy For The Treatment Of Acute Myeloid Leukemia Blood. 122: 3964-3964. DOI: 10.1182/Blood.V122.21.3964.3964  0.319
2013 Kühn MW, Hadler M, Daigle SR, Chen C, Sinha AU, Krivtsov AV, Olhava EJ, Caligiuri MA, Bradner JE, Pollock RM, Armstrong SA. Myeloid Leukemia Cells With MLL partial Tandem Duplication Are Sensitive To Pharmacological Inhibition Of The H3K79 Methyltransferase DOT1L Blood. 122: 1256-1256. DOI: 10.1182/Blood.V122.21.1256.1256  0.322
2013 Armstrong SA. Abstract IA08: Targeting histone methylation in leukemia Cancer Research. 73. DOI: 10.1158/1538-7445.Cec13-Ia08  0.313
2012 Neff T, Sinha AU, Kluk MJ, Zhu N, Khattab MH, Stein L, Xie H, Orkin SH, Armstrong SA. Polycomb repressive complex 2 is required for MLL-AF9 leukemia. Proceedings of the National Academy of Sciences of the United States of America. 109: 5028-33. PMID 22396593 DOI: 10.1073/Pnas.1202258109  0.303
2012 Armstrong SA. Abstract SY35-03: Gene expression and epigenetic programs in leukemia stem cell development Cancer Research. 72. DOI: 10.1158/1538-7445.Am2012-Sy35-03  0.306
2011 Bernt KM, Zhu N, Sinha AU, Vempati S, Faber J, Krivtsov AV, Feng Z, Punt N, Daigle A, Bullinger L, Pollock RM, Richon VM, Kung AL, Armstrong SA. MLL-rearranged leukemia is dependent on aberrant H3K79 methylation by DOT1L. Cancer Cell. 20: 66-78. PMID 21741597 DOI: 10.1016/J.Ccr.2011.06.010  0.307
2010 Pollock RM, Daigle SR, Olhava EJ, Therkelsen CA, Majer CR, Song J, Allain CJ, Sneeringer CJ, Johnston LD, Scott MP, Jin L, Kuntz KW, Chesworth R, Moyer MP, Bernt KM, ... Armstrong S, et al. Selective Killing of Mixed Lineage Leukemia Cells by a Potent Small-Molecule DOT1L Inhibitor Blood. 116: 780-780. DOI: 10.1182/BLOOD.V116.21.780.780  0.32
2010 Bernt KM, Zhu N, Faber J, Punt N, Pollock RM, Richon VM, Kung AL, Armstrong S. Demonstration of a Role for Dot1l In MLL-Rearranged Leukemia Using a Conditional Loss of Function Model Blood. 116: 62-62. DOI: 10.1182/Blood.V116.21.62.62  0.327
2009 Faber J, Krivtsov AV, Stubbs MC, Wright R, Davis TN, van den Heuvel-Eibrink M, Zwaan CM, Kung AL, Armstrong SA. HOXA9 is required for survival in human MLL-rearranged acute leukemias. Blood. 113: 2375-85. PMID 19056693 DOI: 10.1182/Blood-2007-09-113597  0.323
2009 Bernt K, Faber J, Davis TN, Kung A, Armstrong S. DOT1L and Histone H3 Lysine79 Methylation as a Therapeutic Target in Mixed Lineage Leukemia. Blood. 114: 212-212. DOI: 10.1182/Blood.V114.22.212.212  0.308
2007 Faber J, Krivstov AV, Stubbs MC, van den Heuvel-Eibrink M, Kung AL, Zwaan CM, Armstrong SA. The Myocyte Enhancer Factor 2C (MEF2C) Is a Direct Transcriptional Target of HOXA9 and Mediates Leukemia Survival in Human Mixed-Lineage Leukemias. Blood. 110: 58-58. DOI: 10.1182/Blood.V110.11.58.58  0.325
2007 Stubbs MC, Faber J, Kung AL, Cameron S, Armstrong SA. HOXA9 Represses Bim Expression in MLL Rearranged Leukemia: Implications for Drug Therapy. Blood. 110: 57-57. DOI: 10.1182/Blood.V110.11.57.57  0.323
Show low-probability matches.